文献速递胸部CT

动脉期增强CT影像组学模型可可靠预测非小细胞肺癌PD-L1表达及免疫治疗预后:一项回顾性多中心队列研究

Radiomics Models Derived From Arterial-Phase-Enhanced CT Reliably Predict Both PD-L1 Expression and Immunotherapy Prognosis in Non-small Cell Lung Cancer: A Retrospective, Multicenter Cohort Study.
PubMed 文献 · Acad Radiol · 2024-07-31

本研究基于204例非小细胞肺癌患者基线动脉期增强CT提取影像组学特征,用LASSO降维计算肿瘤评分,并以朴素贝叶斯、决策树、XGBoost和随机森林建模。随机森林模型在三分类和两分类场景下训练集与验证集AUC分别为0.98/0.94和0.99/0.93。验证集中仅信迪利单抗组模型预测的PD-L1高表达与治疗反应(AUC=0.859)和生存改善(HR=0.2)相关。

要点

  • 基于基线动脉期增强CT的随机森林影像组学模型在验证集两分类预测PD-L1表达的AUC为0.93(95%CI 0.83-0.98)。
  • 验证集中仅信迪利单抗组模型预测的PD-L1高表达可预测治疗反应(AUC=0.859)。
  • 验证集中仅信迪利单抗组模型预测的PD-L1高表达与生存改善相关(HR=0.2,95%CI 0.08-0.53)。

核心结论

  • 基于动脉期增强CT的影像组学模型是一种潜在的无创方法,可稳健预测非小细胞肺癌患者的PD-L1表达和免疫检查点抑制剂治疗结局。

研究设计与样本

  • 回顾性多中心队列研究,纳入一项已发表多中心临床试验(2018年8月23日启动,2019年11月15日结束,ClinicalTrials.gov: NCT03607539)中204例患者的基线动脉期增强CT图像。

诊断标准与关键数值

  • 训练集146例(来自选定中心),验证集58例(来自其余中心),采用LASSO降维计算肿瘤评分并建模。
  • 随机森林模型在三分类场景下训练集AUC为0.98,验证集AUC为0.94。
  • 随机森林模型在两分类场景下训练集AUC为0.99(95%CI 0.97-1.0,P<0.0001),验证集AUC为0.93(95%CI 0.83-0.98,P<0.0001)。
  • 验证集中仅信迪利单抗组模型预测的PD-L1高表达预测治疗反应AUC=0.859(95%CI 0.7-0.96,P<0.001)。
  • 验证集中仅信迪利单抗组模型预测的PD-L1高表达与生存改善相关HR=0.2(95%CI 0.08-0.53,P=0.001)。

临床应用与阅片要点

  • 模型基于基线动脉期增强CT影像组学特征,可用于无创预测非小细胞肺癌PD-L1表达状态。
  • 随机森林算法在所用四种算法中表现最优。
  • 模型对治疗反应和生存的预测价值仅在验证集信迪利单抗组中观察到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC) and programmed cell death-ligand 1 (PD-L1) is a companion biomarker. This study aims to use baseline arterial-phase enhanced CT (APECT) to construct efficient radiomic models for predicting PD-L1 expression and immunotherapy prognosis in NSCLC.

MATERIALS AND METHODS: We extracted radiomics features from the baseline APECT images of 204 patients enrolled in a published multicenter clinical trial that commenced on August 23, 2018, and concluded on November 15, 2019 (ClinicalTrials.gov: NCT03607539). Of these patients, 146 patients from selected centers were assigned to the training cohort. The least absolute shrinkage and selection operator (LASSO) method was used to reduce dimensionality of radiomics features and calculate tumor scores. Models were created using naive bayes, decision trees, XGBoost, and random forest algorithms according to tumor scores. These models were then validated in an independent validation cohort comprising 58 patients from the remaining centers.

RESULTS: The random forest algorithm outperformed the other methods. In the three-classification scenario, the random forest model achieving the area under the curve (AUC) values of 0.98 and 0.94 in the training and validation cohorts, respectively. In the two-classification scenario, the random forest model achieved AUCs of 0.99 (95%CI: 0.97-1.0, P < 0.0001) and 0.93 (95%CI: 0.83-0.98, P < 0.0001) in the training and validation cohorts, respectively. Furthermore, patients classified as PD-L1 high-expression by this model can predict treatment response (AUC=0.859, 95%CI: 0.7-0.96, P < 0.001) and improved survival (HR=0.2, 95%CI: 0.08-0.53, P = 0.001) only in validation sintilimab arm.

CONCLUSION: Radiomics models based on APECT represent a potential non-invasive approach to robustly predict PD-L1 expression and ICI treatment outcomes in patients with NSCLC, which could significantly improve precision cancer immunotherapy.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Liu Z, Yao Y, Zhao M, et al. Radiomics Models Derived From Arterial-Phase-Enhanced CT Reliably Predict Both PD-L1 Expression and Immunotherapy Prognosis in Non-small Cell Lung Cancer: A Retrospective, Multicenter Cohort Study. Acad Radiol. 2024. PMID: 39084935. doi:10.1016/j.acra.2024.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。